Targeted Therapeutics that Address Unmet Medical Needs

Inflammatory Bowel Disease (IBD) is complex and heterogeneous. A ‘one-size-fits-all’ standardized treatment may not be effective for many patients. In fact, 75% of the 2 million patients in the US who have IBD are refractory to first line biologic therapy¹.

Prometheus Biosciences is pioneering a precision medicine approach for the treatment of IBD. We merge access to hundreds of thousands of patient samples with advances in machine learning and data mining tools to understand the link between patients’ symptoms and disease-driving biomarkers. We use these breakthroughs to identify novel therapeutic targets and diagnostic tests to address the unmet medical needs. 

Therapeutic Pipeline

Program
Discovery
Lead Optimization
IND-Enabling
Phase 1
Phase 2
Phase 3
Partner
PRA023 - Anti-TL1A mAb
PR600 - Anti-TNF Super Family Member mAb
(1)
Europe Partnered
PR300 - Small Molecule GPCR Modulator
TPR15 - mAb
(2)

1) Prometheus retains all commercialization rights to PR600 outside of Europe, Australia and New Zealand
2) We are developing a companion diagnostic in tandem with Takeda's drug discovery and development efforts. Takeda has an option to collaborate on an additional program.

ProgramProgress
PRA023 IND-Enabling
PR600 Discovery
PR300 Discovery
TPR15 Discovery

Core Research Principles

The target is a true driver of disease in a defined IBD sub-phenotype

We can develop a selective medicine that has best-in-class potential

We can identify pathway-specific enrichment biomarkers

We can pre-identify and enroll the appropriate patients

Allowing us to deliver drugs with

  • superior label claims, first-line use
  • an accelerated, efficient path to the clinical and market

Reference:
1. Singh S. Fumery M, Sandborn WJ, Murad MH. Systemic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn’s disease. Aliment Pharmacol Ther. 2018 ;48:394–409